Disclosed herein are triterpenoid compounds, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also disclosed herein are methods of their use for treat.

##STR00001##

A number of triterpene saponin variants with different modifications on their central glycosyl ester linkage are described. Also described are methods of making and method of using such triterpene saponin variants.

The present disclosure relates to Betulastatin compounds, pharmaceutical compositions and kits comprising such compounds, and methods for using such compounds or pharmaceutical compositions.

In some aspects, the present disclosure provides compounds of the formula: (I) and (II), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.

##STR00001##

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: ##STR00001##
with X selected from C.sub.4-8 cycloalkyl, C.sub.4-8 cycloalkenyl, C.sub.4-9 spirocycloalkyl, C.sub.4-9 spirocycloalkenyl, C.sub.4-8 oxacycloalkyl, C.sub.4-8 dioxacycloalkyl, C.sub.6-8 oxacycloalkenyl, C.sub.6-8 dioxacycloalkenyl, C.sub.6 cyclodialkenyl, C.sub.6 oxacyclodialkenyl, C.sub.6-9 oxaspirocycloalkyl and C.sub.6-9 oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is —C.sub.1-6 alkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein t, R.sup.7, R.sup.3, R.sup.9, R.sup.6a, R.sup.6b, R.sup.11a, R.sup.11b, R.sup.15a, R.sup.15b, R.sup.16a, R.sup.16b, R.sup.17a, R.sup.17b, R.sup.18a, R.sup.18b, R.sup.19a, R.sup.19b, R.sup.5a, R.sup.5b, R.sup.8 and R.sup.13 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

##STR00001##

Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein t, R.sup.7, R.sup.3, R.sup.9, R.sup.6a, R.sup.6b, R.sup.11a, R.sup.11b, R.sup.15a, R.sup.15b, R.sup.16a, R.sup.16b, R.sup.17a, R.sup.17b, R.sup.18a, R.sup.18b, R.sup.19a, R.sup.19b, R.sup.5a, R.sup.5b, R.sup.8 and R.sup.13 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

##STR00001##

The present disclosure relates to Betulastatin compounds, pharmaceutical compositions and kits comprising such compounds, and methods for using such compounds or pharmaceutical compositions.

The present invention relates to compound of Formula I or a pharmaceutically acceptable salt thereof

##STR00001##

wherein R.sup.1 is

##STR00002##

where the squiggly line indicates the point of attachment to the rest of the molecule;
R.sup.2 is F or

##STR00003##

where the squiggly line indicates the point of attachment to the rest of the molecule;
R.sup.3 is H or CH.sub.3;
Z is O or is absent; and
R.sup.4 is —OC.sub.1-3alkyl, C.sub.1-30alkyl, or —N(CH.sub.3).sub.2.

Methods for synthesizing amooranin (25-hydroxy-3-oxoolean-12-en-28-oic acid (AMR) and/or amooranin analogs, including amooranin methyl ester (AMR-Me), by using oleanolic acid in an oxidation process, and therapeutic uses thereof are described.